NNNN
Anbio Biotechnology
NASDAQ · Healthcare · Medical - Instruments & Supplies · DE
$3.27
+4.47%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -28.4%
- EBITDA
- -16.8%
- EBIT
- -17.3%
- Net income
- -13.8%
- EPS
- +32.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025